| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
14,310,000 |
| Market
Cap: |
29.48(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.12 - $2.85 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Eledon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis. Co.'s lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a biological target. AT-1501 is engineered to improve safety and provide pharmacokinetic, pharmacodynamic and dosing advantages. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,978,932 |
1,979,932 |
| Total Buy Value |
$0 |
$0 |
$0 |
$2,597 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lampert Mark N |
10% Owner |
– – • |
2023-05-05 |
4 |
B |
$0.00 |
$0 |
D/D |
1,978,932 |
145,029 |
2.37 |
-56% |
|
| Perrin Steven |
President |
• • – |
2022-11-23 |
4 |
B |
$2.60 |
$2,597 |
D/D |
1,000 |
1,000 |
2.73 |
-25% |
|
| Lampert Mark N |
10% Owner |
– – • |
2022-01-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,309,073 |
|
-20% |
|
| Gros David-Alexandre C |
Chief Executive Officer |
• • – |
2021-12-20 |
4 |
B |
$4.48 |
$8,960 |
D/D |
2,000 |
9,000 |
2.81 |
-34% |
|
| Gros David-Alexandre C |
Chief Executive Officer |
• • – |
2021-08-17 |
4 |
B |
$6.21 |
$24,840 |
D/D |
4,000 |
7,000 |
2.81 |
-31% |
|
| Little Paul Sean |
CHIEF FINANCIAL OFFICER |
• – – |
2021-06-11 |
4 |
B |
$8.87 |
$88,700 |
D/D |
10,000 |
10,000 |
2.74 |
-38% |
|
| Gros David-Alexandre C |
Chief Executive Officer |
• • – |
2021-06-09 |
4 |
B |
$8.01 |
$24,030 |
D/D |
3,000 |
3,000 |
2.81 |
-30% |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,289,628 |
113,152 |
|
- |
|
| Logos Global Management Lp |
10% Owner |
– – • |
2020-10-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
145,000 |
|
-47% |
|
| Logos Global Management Lp |
10% Owner |
– – • |
2020-10-30 |
4 |
B |
$24.03 |
$2,341,714 |
I/I |
92,040 |
224,071 |
1.5 |
-47% |
|
| Logos Global Management Lp |
10% Owner |
– – • |
2020-10-30 |
4 |
S |
$26.64 |
$345,559 |
I/I |
(12,969) |
199,973 |
|
47% |
|
| Lampert Mark N |
10% Owner |
– – • |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
193,931 |
|
10% |
|
| Kuwahara Jon |
See Remarks |
• – – |
2019-05-21 |
4 |
S |
$1.91 |
$2,022 |
D/D |
(1,058) |
5,974 |
|
- |
|
| Flesher Gregory J. |
Chief Executive Officer |
• • – |
2019-05-21 |
4 |
S |
$1.91 |
$5,614 |
D/D |
(2,937) |
156,918 |
|
- |
|
| Turkel Catherine C. |
President |
• – – |
2019-05-21 |
4 |
S |
$1.91 |
$3,658 |
D/D |
(1,914) |
88,662 |
|
- |
|
| Kuwahara Jon |
See Remarks |
• – – |
2019-05-20 |
4 |
S |
$1.96 |
$8,274 |
D/D |
(4,218) |
7,032 |
|
- |
|
| Flesher Gregory J. |
Chief Executive Officer |
• • – |
2019-05-20 |
4 |
S |
$1.96 |
$22,953 |
D/D |
(11,701) |
159,855 |
|
- |
|
| Turkel Catherine C. |
President |
• – – |
2019-05-20 |
4 |
S |
$1.96 |
$14,953 |
D/D |
(7,623) |
90,576 |
|
- |
|
| Chimovits Erez |
Director |
– • – |
2019-05-02 |
4 |
B |
$3.10 |
$2,003,232 |
I/I |
646,204 |
3,183,314 |
2.1 |
- |
|
| Orbimed Israel Biofund Gp Limited Partnership |
Director |
– • • |
2019-05-02 |
4 |
B |
$3.10 |
$2,003,232 |
I/I |
646,204 |
3,183,314 |
2.25 |
- |
|
| Yook Paul |
10% Owner |
– – • |
2019-04-30 |
4 |
S |
$2.70 |
$540 |
I/I |
(200) |
1,065,867 |
|
- |
|
| Flesher Gregory J. |
Chief Executive Officer |
• • – |
2019-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
171,556 |
|
- |
|
| Turkel Catherine C. |
President |
• – – |
2019-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
98,199 |
|
- |
|
| Turkel Catherine C. |
President |
• – – |
2018-09-12 |
4 |
B |
$5.02 |
$83,476 |
D/D |
16,632 |
78,199 |
2.74 |
- |
|
| Turkel Catherine C. |
President |
• – – |
2018-09-11 |
4 |
B |
$4.56 |
$77,671 |
D/D |
17,048 |
61,567 |
2.74 |
- |
|
89 Records found
|
|
Page 1 of 4 |
|
|
0.04 (1.98%) 
